- Home
- SRZN vs OTLK Comparison
SRZN vs OTLK Comparison
Compare SRZN & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRZN | OTLK |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | 59 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.6M | 249.6M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SRZN | OTLK |
|---|---|---|
| Price | $17.43 | $0.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $38.00 | $2.50 |
| AVG Volume (30 Days) | 172.1K | ★ 5.4M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | N/A | ★ N/A |
| Revenue | $3,477,000.00 | ★ $8,146,123.00 |
| Revenue This Year | $75.35 | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.39 | $0.16 |
| 52 Week High | $35.00 | $2.54 |
Technical Indicators
Market Signals| Indicator | SRZN | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 23.83 | 46.10 |
| Support Level | N/A | $0.68 |
| Resistance Level | $23.55 | $0.94 |
| Average True Range (ATR) | 1.29 | 0.04 |
| MACD | -0.42 | 0.02 |
| Stochastic Oscillator | 4.15 | 72.84 |
Price Performance
Historical ComparisonAbout SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.